A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $121 to $255
Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Biogen Emerging as 'Leaner, Less Risky' Company, RBC Says
Biogen Is Maintained at Buy by Canaccord Genuity
Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265
HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $144 to $220
Baird Maintains Outperform on Biogen, Lowers Price Target to $255
Express News | Needham Reiterates Hold on Biogento Hold
Biogen Analyst Ratings
Express News | Biogen : TD Cowen Cuts Target Price to $175 From $200
Biogen Inc. Reports Strong Q1 2025 Results
Express News | Biogen : Oppenheimer Cuts Target Price to $205 From $255
Biogen Inc. Earnings Call Highlights Growth and Challenges
Express News | Biogen Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Biogen | 10-Q: Q1 2025 Earnings Report
Research Alert: CFRA Keeps Hold View On Shares Of Biogen Inc.
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen's Q1 Revenue Soars Past Estimates as Rare Disease Pivot Pays off